Lapyrium

Summary

Lapyrium (CHEMBL1201786) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 363.5 Da · C21H35N2O3+

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201786
Name	Lapyrium
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	22660
Molecular formula	C21H35N2O3+
Molecular weight	363.5
InChIKey	UGJWZYARKOFRDB-UHFFFAOYSA-O

SMILES: CCCCCCCCCCCC(=O)OCCNC(=O)C[N+]1=CC=CC=C1

IUPAC name: 2-[(2-pyridin-1-ium-1-ylacetyl)amino]ethyl dodecanoate

Also known as: Lapyrium cation, Lapyrium ion

Parent form; salt/anhydrous children: CHEMBL1201787

Patent coverage: 10 distinct patent families (17 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).